Zacks Analyst Blog Highlights: Amgen, Novartis, GlaxoSmithKline, Merck and Eli Lilly - Press Releases

For Immediate Release

Chicago, IL – June 3, 2010 – Zacks.com Analyst Blog features: Amgen Inc. (AMGN), Novartis (NVS), GlaxoSmithKline (GSK), Merck (MRK) and Eli Lilly (LLY).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s Analyst Blog:

Amgen’s Prolia Approved in U.S.

Amgen Inc. (AMGN) is on a roll with its key pipeline candidate, Prolia, receiving back to back approval in both the EU and the US. While Prolia gained approval in the EU for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, the US Food and Drug Administration (FDA) approved the product for the treatment of osteoporosis in postmenopausal women at increased risk of fractures or patients who have failed or are intolerant to other osteoporosis treatments.

The FDA approval, which came more than a month before the action date of July 25, is a major boost for Amgen. Prolia has been competitively priced at $825 per 60 mg injection, and will be available from next week along with a Risk Evaluation and Mitigation Strategy (REMS).

Although treatments for the postmenopausal osteoarthritis (PMO) indication are currently available, Prolia could have an advantage over existing treatment options due to its convenient dosing regimen. Prolia needs to be injected only twice a year as opposed to other treatments, which require more frequent dosing.

Prolia’s approval is a major positive for Amgen. Based on encouraging phase III results, we believe the product has the potential to capture a major share of the osteoporosis market once launched. We believe the drug has blockbuster potential.

Amgen is also looking to get the drug approved for the delay of skeletal-related events in patients with advanced cancer. A biologics license application (BLA), with data from several studies including three pivotal phase III studies comparing Prolia with Novartis' (NVS) Zometa was submitted recently.

While Amgen has a collaboration and licensing agreement for Prolia with Daiichi-Sankyo for Japan, the company has a collaboration agreement with GlaxoSmithKline (GSK) for Prolia for the postmenopausal osteoporosis indication in Europe, Australia, New Zealand and Mexico.

With all the key products expected to lose patent protection in the next few years, Prolia’s approval is an important event for Amgen. We expect investor focus to remain on the successful launch and commercialization of the product. Prolia will compete primarily with Merck's (MRK) Fosamax, GlaxoSmithKline’s Boniva, Eli Lilly's (LLY) Evista and Forteo for a share of the osteoporosis market. We currently have a Neutral recommendation on Amgen.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com